• Legend Biotech posted first-quarter results with revenue rising 56% to USD 305.1 million, while net loss narrowed to USD 54.3 million from USD 101 million a year earlier.
• Collaboration revenue climbed 61% to USD 298.4 million, reflecting higher CARVYKTI sales under the Janssen Agreement.
• CARVYKTI net trade sales increased 62% year over year to about USD 597 million, driven by 36% growth in the U.S. and 222% growth outside the U.S.
• Cash and cash equivalents plus time deposits totaled USD 834.6 million at March 31, 2026; management said this should fund operations beyond 2026, when it expects to achieve company-wide profit on an adjusted net income basis.
• Availability expanded to 18 markets following launches in Italy, Poland, Czech Republic, and Australia; manufacturing success rate reached 99% with more than 95% on-time order releases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.